The objective was to estimate direct medical costs for non-vertebral fractures in the first year of therapy among risedronate, alendronate, and nasal calcitonin patients utilizing an integrated administrative, medical and pharmacy claims database. METHODS: A retrospective cohort study was conducted among 5024 women and men (aged 45+) with a new prescription for risedronate (5 mg/day, or 30 mg/week), alendronate (5 mg/day, 10 mg/day, 35 mg/week or 70 mg/week), or nasal calcitonin (200I.U./day) between July 1, 2000, and June 30, 2001. Non-vertebral fracture-related direct medical costs (inpatient and outpatient care) were assessed for a 12-month period following initiation of the bisphosphonate or nasal calcitonin therapy using 2003 Medicare fee schedule payments. Sites at which a patient had a clinical fracture in the 6 months prior to initiation of therapy were excluded from the analysis. RESULTS: During the capture period patients were treated with alendronate (74%), risedronate (13%), and nasal calcitonin (13%). There were no baseline differences in age, gender or number of concomitant medications between risedronate and alendronate patients. Nasal calcitonin patients, however, were significantly older and had higher concomitant medications use than both risedronate and alendronate patients. Alendronate patients incurred almost three times the fracture-related costs of risedronate patients ($124 vs. $45, p = 0.019). Nasal calcitonin patients incurred more than four times the fracture-related costs of risedronate patients ($198 vs. $45, p = 0.028) in an adjusted model. Alendronate patients did not have significantly different fracture-related costs than nasal calcitonin patients. CONCLU-SIONS: Observed fracture-related costs among patients initiating risedronate therapy were lower than fracture-related costs among patients of similar characteristics who initiated alendronate therapy. OBJECTIVES: Teriparatide has shown improved efficacy in increasing bone mineral density and decreasing nonvertebral fractures in comparison to alendronate. The cost-effectiveness of teriparatide over bisphosphonates has not been evaluated in the VA Health System. This decision model seeks to evaluate all relevant resource utilization and associated costs of osteoporosis treatment with teriparatide compared to bisphosphonates to determine the cost-effectiveness of each intervention in a highrisk population. METHODS: The study was performed from the government payer perspective. Resource utilization was ascertained from published literature and relevant VA databases. Outcomes data was reviewed and incorporated from published trials and FDA reviews of teriparatide, alendronate, and risedronate into an event targeted decision tree model. Pertinent utilization rates and costs were captured including: emergency services, hospitalization costs associated with fracture, osteoporosis drug therapy costs, additional medication costs associated with fracture, rehabilitation costs, outpatient visits, and nursing and home health care costs. Outcome measurements include annualized cost of treatment per vertebral and non-vertebral fractures over a 2-year period. The decision tree was built with TreeAge®. Crystal Ball® 2000 was used to perform the model analysis. RESULTS: Compared to bisphosphonates, teriparatide demonstrated fewer osteoporotic fractures and reduced total cost of treatment. Although the VA medication acquisition cost of teriparatide is greater than ten times the cost of bisphosphonates, this cost is offset by reduction in health care utilization costs. The primary cost drivers were medications, hospitalizations, rehabilitation, and nursing home costs. The total cost of treatment for teriparatide was US$1,363,868 versus US$1,776,412 for bisphosphonates, with corresponding fracture rates of 11.35 and 18.19 per 100 patients, respectively. CONCLUSIONS: This model suggests that teriparatide may be a cost effective therapy in the treatment of high-risk osteoporosis patients from the perspective of the VA. The advantage of teriparatide over bisphosphonates may be attributed to the substantial differences in fracture rates. Antiresoprtive therapies are used to prevent further fracture in men and women with osteoporosis. However, patients with severe osteoporosis may continue to fracture despite this therapy. New trials have shown that teriparatide (Forteo) is efficacious in preventing new vertebral and non-vertebral fractures in patients who have already experienced a vertebral fracture. OBJEC-TIVES: This study aimed to assess the cost-effectiveness of teriparatide in preventing osteoporotic fractures in this population.
POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS
Ohsfeldt RL 1 , Borisov NN 2 , Sheer RL 2 , Lindsay R 3 1 College of Public Health, University of Iowa, Iowa City, IA, USA; 2 Procter and Gamble Pharmaceuticals, Mason, OH, USA; 3 Regional Bone Center, Helen Hayes Hospital, Stony Point, NY, USA OBJECTIVES: The objective was to estimate direct medical costs for non-vertebral fractures in the first year of therapy among risedronate, alendronate, and nasal calcitonin patients utilizing an integrated administrative, medical and pharmacy claims database. METHODS: A retrospective cohort study was conducted among 5024 women and men (aged 45+) with a new prescription for risedronate (5 mg/day, or 30 mg/week), alendronate (5 mg/day, 10 mg/day, 35 mg/week or 70 mg/week), or nasal calcitonin (200I.U./day) between July 1, 2000, and June 30, 2001 . Non-vertebral fracture-related direct medical costs (inpatient and outpatient care) were assessed for a 12-month period following initiation of the bisphosphonate or nasal calcitonin therapy using 2003 Medicare fee schedule payments. Sites at which a patient had a clinical fracture in the 6 months prior to initiation of therapy were excluded from the analysis. RESULTS: During the capture period patients were treated with alendronate (74%), risedronate (13%), and nasal calcitonin (13%). There were no baseline differences in age, gender or number of concomitant medications between risedronate and alendronate patients. Nasal calcitonin patients, however, were significantly older and had higher concomitant medications use than both risedronate and alendronate patients. Alendronate patients incurred almost three times the fracture-related costs of risedronate patients ($124 vs. $45, p = 0.019). Nasal calcitonin patients incurred more than four times the fracture-related costs of risedronate patients ($198 vs. $45, p = 0.028) in an adjusted model. Alendronate patients did not have significantly different fracture-related costs than nasal calcitonin patients. CONCLU-SIONS: Observed fracture-related costs among patients initiating risedronate therapy were lower than fracture-related costs among patients of similar characteristics who initiated alendronate therapy.
POS6 TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK OSTEOPOROSIS PATIENTS: A DECISION MODEL ANALYSIS
Hendley YG 1 , DeLattre ML 2 , Schaefer MG 3 , Boggie DT 2 , Tuey C 2 1 University of the Pacific, La Jolla, CA, USA; 2 VA San Diego Health care System, San Diego, CA, USA; 3 Kansas City VA Medical Center, Kansas City, MO, USA OBJECTIVES: Teriparatide has shown improved efficacy in increasing bone mineral density and decreasing nonvertebral fractures in comparison to alendronate. The cost-effectiveness of teriparatide over bisphosphonates has not been evaluated in the VA Health System. This decision model seeks to evaluate all relevant resource utilization and associated costs of osteoporosis treatment with teriparatide compared to bisphosphonates to determine the cost-effectiveness of each intervention in a highrisk population. METHODS: The study was performed from the government payer perspective. Resource utilization was ascertained from published literature and relevant VA databases. Outcomes data was reviewed and incorporated from published trials and FDA reviews of teriparatide, alendronate, and risedronate into an event targeted decision tree model. Pertinent utilization rates and costs were captured including: emergency services, hospitalization costs associated with fracture, osteoporosis drug therapy costs, additional medication costs associated with fracture, rehabilitation costs, outpatient visits, and nursing and home health care costs. Outcome measurements include annualized cost of treatment per vertebral and non-vertebral fractures over a 2-year period. The decision tree was built with TreeAge®. Crystal Ball® 2000 was used to perform the model analysis. RESULTS: Compared to bisphosphonates, teriparatide demonstrated fewer osteoporotic fractures and reduced total cost of treatment. Although the VA medication acquisition cost of teriparatide is greater than ten times the cost of bisphosphonates, this cost is offset by reduction in health care utilization costs. The primary cost drivers were medications, hospitalizations, rehabilitation, and nursing home costs. The total cost of treatment for teriparatide was US$1,363,868 versus US$1,776,412 for bisphosphonates, with corresponding fracture rates of 11.35 and 18.19 per 100 patients, respectively. CONCLUSIONS: This model suggests that teriparatide may be a cost effective therapy in the treatment of high-risk osteoporosis patients from the perspective of the VA. The advantage of teriparatide over bisphosphonates may be attributed to the substantial differences in fracture rates.
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COST-EFFECTIVENESS OF TERIPARATIDE (FORTEO) IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AMONG MEN AND POSTMENOPAUSAL WOMEN IN AUSTRALIA
Graham-Clarke PL 1 , Lees M 2 , Wolthers T 1 , Thiebaud D 1 , Price N 2 1 Eli Lilly, Australia, West Ryde, NSW, Australia; 2 M-TAG Pty Ltd, Chatswood, NSW, Australia Antiresoprtive therapies are used to prevent further fracture in men and women with osteoporosis. However, patients with severe osteoporosis may continue to fracture despite this therapy. New trials have shown that teriparatide (Forteo) is efficacious in preventing new vertebral and non-vertebral fractures in patients who have already experienced a vertebral fracture. OBJEC-TIVES: This study aimed to assess the cost-effectiveness of teriparatide in preventing osteoporotic fractures in this population.
METHODS:
A cost-utility model was developed to compare teriparatide with no therapy (placebo) in a population of osteoporotic patients with prior fracture. This model is a Markov process estimated using Monte Carlo simulation. Relative efficacy assumptions in the model are based solely on the results of randomised controlled trials (Neer et al., 2001) , while the baseline probability of fracture is derived from Australian epidemiological data (Sanders et al., 1999) . The cost-effectiveness of teriparatide was assessed in terms of its impact in preventing new vertebral and non-vertebral fractures in a cohort with at least one prior radiologically confirmed vertebral fracture and an average age of 70 years. The model was designed so that the risk of further vertebral fracture rises with each fracture. The model ran for a ten-year period. Teriparatide is provided for 18 months, after which patients have the choice of receiving a bisphosphonate or no additional therapy for a further 42 months. RESULTS: Over the 10-year period, teriparatide is associated with an increased cost of AUD$7337 ($US5503) and a gain of 0.4168 QALYs per patient compared with no treatment. Hence, the incremental cost per QALY gained with teriparatide compared with no treatment in this population was AUD$17,603 (US$13, 202) . Extensive sensitivity analyses indicated these results were robust. CONCLUSIONS: Teriparatide is a costeffective therapy to reduce the risk of future fractures in men and women with prior osteoporotic vertebral fracture.
